<i>GHSR</i> hypermethylation: a promising pan-cancer marker

Jandaghi, Pouria; Hoheisel, Jörg D.; Riazalhosseini, Yasser

doi:10.1080/15384101.2015.1006051

Cited by 11 publications

(12 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the list of 180 genes, CDH13, COL14A1, HAAO, HAND2, HS3ST2, HTR1B, NPY, and ZNF177, have been reported in endometrial cancer samples in independent studies (17-19, 21, 27). Because different cancers may have common pathways, the hypermethylated genes identified in our gene list might also be methylated in other cancers, and ADHFE1, CDO1, DPP6, EFS, FEZF2, GHSR, GRIA4, NEFL, PARP15, PAX6, SSTR1, and TRH have been reported (28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40). We have identified for the first time hypermethylation of BHLHE22, CCDC140, CELF4, GALNTL6, ZNF334, and ZNF662 in cancers.…”

Section: Discussionmentioning

confidence: 75%

Integrated Epigenomics Analysis Reveals a DNA Methylation Panel for Endometrial Cancer Detection Using Cervical Scrapings

Huang

Liao

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 75%

Integrated Epigenomics Analysis Reveals a DNA Methylation Panel for Endometrial Cancer Detection Using Cervical Scrapings

Huang

Liao

et al. 2017

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…GHSR encodes a member of the G-protein coupled receptor (GPCR) family and has 2 transcript variants, GHSR 1a and 1b (16). Previous studies have demonstrated that GHSR is aberrantly hypermethylated in a number of cancers (e.g., lung, breast, prostate, pancreatic and colorectal cancers, glioblastoma, and B-cell chronic lymphocytic leukemia) and its methylation levels may be used to discriminate between cancer and healthy tissue, with GHSR hypermethylation being an early cancer event (11,17,18). GPCR, comprising α, β, and γ subunits, responds to various extracellular stimuli, such as hormones, growth factors and sensory stimulating signals.…”

Section: Gng4 Hoxd9 Ghsr Sall3 --------------------------------------mentioning

confidence: 99%

“…The frequency of GHSR methylation increased in the order of the thymus, thymoma and TC. Jandaghi et al reported that GHSR hypermethylation is a pan-cancer marker regardless of the tissue from which the tumor originates (18). GHSR may be involved in TC and thymoma.…”

Section: Gng4 Hoxd9 Ghsr Sall3 --------------------------------------mentioning

confidence: 99%

DNA methylation of GHSR, GNG4, HOXD9 and SALL3 is a common epigenetic alteration in thymic carcinoma

et al. 2019

View full text Add to dashboard Cite

Thymic epithelial tumors comprise thymoma, thymic carcinoma and neuroendocrine tumors of the thymus. Recent studies have revealed that the incidence of somatic non-synonymous mutations is significantly higher in thymic carcinoma than in thymoma. However, limited information is currently available on epigenetic alterations in these types of cancer. In this study, we thus performed genome-wide screening of aberrantly methylated CpG islands in thymoma and thymic carcinoma using Illumina HumanMethylation450 K BeadChip. We identified 92 CpG islands significantly hypermethylated in thymic carcinoma in relation to thymoma and selected G protein subunit gamma 4 (GNG4), growth hormone secretagogue receptor (GHSR), homeobox D9 (HOXD9) and spalt like transcription factor 3 (SALL3), which are related to cancer. We examined the promoter methylation of 4 genes in 46 thymic epithelial tumors and 20 paired thymus tissues using bisulfite pyrosequencing. Promoter methylation was significantly higher in thymic carcinoma than in thymoma and revealed a high discrimination between thymic carcinoma and thymoma in all 4 genes. Promoter methylation was higher in thymic carcinoma than in the thymus. No significant differences were observed in the promoter methylation of GNG4, HOXD9, or SALL3 between thymoma and the thymus. The promoter methylation of the 4 genes was not significantly higher in advanced-stage tumors than in early-stage tumors in all thymic epithelial tumors. Among the 4 genes, relapse-free survival was significantly worse in tumors with a higher DNA methylation than in those with a lower DNA methylation in all thymic epithelial tumors. Moreover, relapse-free survival was significantly worse in thymomas with a higher DNA methylation of HOXD9 and SALL3 than in those with a lower DNA methylation. On the whole, the findings of this study indicated that the promoter methylation of cancer-related genes was significantly higher in thymic carcinoma than in thymoma and the thymus. This is a common epigenetic alteration of high diagnostic value in thymic carcinoma and may be involved in the carcinogenesis of thymic carcinoma. However, epigenetic alterations in the 3 genes, apart from GHSR, are not involved in the tumorigenesis of thymoma.

show abstract

“…The majority of DNA methylation markers that hold promise for EC detection have been derived from studies on EC, but also markers developed for cervical cancer detection showed potential diagnostic relevance for EC detection [ 33 ]. We considered the markers GHSR, SST and ZIC1 as interesting candidates to evaluate the detection of EC in the urine by DNA methylation marker testing, based on our previous studies on urinary methylation markers and their diagnostic marker potential for different cancer types [ 22 , 23 , 25 , 34 ].…”

Section: Introductionmentioning

confidence: 99%

Non-invasive detection of endometrial cancer by DNA methylation analysis in urine

et al. 2020

View full text Add to dashboard Cite

Background The incidence of endometrial cancer is rising, and current diagnostics often require invasive biopsy procedures. Urine may offer an alternative sample type, which is easily accessible and allows repetitive self-sampling at home. Here, we set out to investigate the feasibility of endometrial cancer detection in urine using DNA methylation analysis. Results Urine samples of endometrial cancer patients (n = 42) and healthy controls (n = 46) were separated into three fractions (full void urine, urine sediment, and urine supernatant) and tested for three DNA methylation markers (GHSR, SST, ZIC1). Strong to very strong correlations (r = 0.77–0.92) were found amongst the different urine fractions. All DNA methylation markers showed increased methylation levels in patients as compared to controls, in all urine fractions. The highest diagnostic potential for endometrial cancer detection in urine was found in full void urine, with area under the receiver operating characteristic curve values ranging from 0.86 to 0.95. Conclusions This feasibility study demonstrates, for the first time, that DNA methylation analysis in urine could provide a non-invasive alternative for the detection of endometrial cancer. Further investigation is warranted to validate its clinical usefulness. Potential applications of this diagnostic approach include the screening of asymptomatic women, triaging women with postmenopausal bleeding symptoms, and monitoring women with increased endometrial cancer risk.

show abstract

GHSR hypermethylation: a promising pan-cancer marker

Cited by 11 publications

References 6 publications

Integrated Epigenomics Analysis Reveals a DNA Methylation Panel for Endometrial Cancer Detection Using Cervical Scrapings

Integrated Epigenomics Analysis Reveals a DNA Methylation Panel for Endometrial Cancer Detection Using Cervical Scrapings

DNA methylation of GHSR, GNG4, HOXD9 and SALL3 is a common epigenetic alteration in thymic carcinoma

Non-invasive detection of endometrial cancer by DNA methylation analysis in urine

Contact Info

Product

Resources

About